Assessment of MUcociLiary Transport timE in CRSwNP Patients in Treatment With Dupilumab: AMULET Study
Alessia Giorli, Fabio Ferretti, Antonio Romano, Marco Casiraghi, Mariella Scarano, Paolo Farneti, Giacomo Sollini, Marco Mandalà, Ernesto Pasquini, Cesare Biagini · 2026
Read Assessment of MUcociLiary Transport timE in CRSwNP Patients in Treatment With Dupilumab: AMULET Study by Alessia Giorli, Fabio Ferretti, Antonio Romano, Marco Casiraghi, Mariella Scarano, Paolo Farneti, Giacomo Sollini, Marco Mandalà, Ernesto Pasquini, Cesare Biagini (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13432524.txt.
Description
Giorli and colleagues ran the AMULET study on 40 adults with severe chronic rhinosinusitis with nasal polyps. All were treated with dupilumab, an antibody blocking interleukin-4 and interleukin-13 signals. The team asked whether the drug restores mucociliary transport. That is the nose's self-cleaning conveyor of beating cilia. Transport time in these patients is markedly prolonged, leaving mucus thick and stagnant.
At baseline the mean transport time was 28.53 minutes, far slower than healthy clearance. Within the first treatment interval it fell to 16.60 minutes in this patient group. By the second recorded visit it had normalized at 13.35 minutes on average. Values kept easing to 11.05 minutes by the final visit. Every patient had normalized by twelve months of therapy. Nearly all participants, 95 percent, were excellent or good responders. The authors propose transport time as a marker of mucosal recovery.
Catalog record
| CREATOR | Alessia Giorli, Fabio Ferretti, Antonio Romano, Marco Casiraghi, Mariella Scarano, Paolo Farneti, Giacomo Sollini, Marco Mandalà, Ernesto Pasquini, Cesare Biagini |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |